Related Experiment Video
Updated: Feb 15, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
Oshrat Hershkovitz-Rokah1,2,3, Dana Pulver1,2,3, Georg Lenz4,5
1Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel, Israel.
Abstract:
Mantle cell lymphoma (MCL) is a lymphoproliferative disorder comprising about 6-10% of all B cell lymphoma cases. Ibrutinib is an inhibitor of Bruton tyrosine kinase (BTK), a key component of early B-cell receptor (BCR) signalling pathways. Although treatment with ibrutinib has significantly improved the outcome of MCL patients, approximately one-third of the patients have primary drug resistance while others appear to develop acquired resistance. Understanding the molecular events leading to the primary and acquired resistance to ibrutinib is essential for achieving better outcomes in patients with MCL. In this review, we describe the biology of the BCR signalling pathway and summarize the landmark clinical trials that have led to the approval of ibrutinib. We review the molecular mechanisms underlying primary and acquired ibrutinib resistance as well as recent studies dealing with overcoming ibrutinib resistance.
Related Concept Videos
Treatment Resistant Cancers
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
Resistivity
Resistance
Quantitative Aspects of Drug-Receptor Interaction
Molecular Models

